Published
1 month agoon
By
Adam BeechOpterion was founded in 2012 by scientist Guido Grentzmann. The company is developing a novel peritoneal dialysis (PD) solution, aiming to revolutionise the dialysis market.
Peritoneal dialysis (PD) uses the body’s own peritoneal membrane within the abdomen as the filter to clean the blood. This procedure can be self-administered at home or on the move.
The money was exclusively raised from a limited number of professional private and institutional investors based in Switzerland and Germany. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into phase one.
Grentzmann said: “The PD market has not seen any significant innovation for over two decades. Hence, there is a high unmet medical need for a novel solution that not only offers better therapy outcomes, but also has the potential for reduced side effects, improved quality of life and higher survival rates of dialysis patients.
“Over 45% of dialysis patients suffer from diabetes, and an increasing number of patients no longer want to visit a clinic or a hospital for their therapy. This is especially true in times of pandemic, as we are currently experiencing.
“Therefore, our glucose-free PD solution is a much-needed innovation not only for the very large number of diabetic dialysis patients, but also for dialysis patients who want to improve their quality of life by having their therapy at home.”
Andreas Schmidt, CFO of Opterion, added: “Thanks to the very successful completion of our financing round – which was oversubscribed by more than 40% – Opterion is now in the position of being very comfortably financed for the next two years.
“This gives us the opportunity to execute our scientific as well as manufacturing plans and prepare for phase one with full speed.”
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.